Xoma News

XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, today announced that, as a result of an improvement in the Company's financial status and in particular its full repayment of an outstanding loan, at the Company's request, its independent registered public accounting firm, Ernst & Young LLP, has agreed to remove a ...

XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that it received a Letter of Reprimand from the staff of The NASDAQ Stock Market LLC on December 8, 2009 for non-compliance with NASDAQ's Listing Rule 5635 in connection with XOMA's previously-announced common share financing completed on September 30, 2009.

Prior to joining the company, Neal was acting chief executive officer of Entelos Inc, a biosimulation company.

Despite the economic recession and past doubts about its financial well-being, one Bay Area company has experienced a welcome surge in profits this year.

Maybe it was a slap across the face. Maybe a wake-up call. Either way, nobody at Xoma liked to be called a "Biotech Zombie.'' The Berkeley-based company was given the moniker by the New York Times in a 2007 feature article because it never "died" despite constantly bleeding money without a marketable product.

XOMA Ltd. November 9, 2009 9:00 am ET Executives Analysts Matthew Kaplan a ' Ladenburg Thalmann & Co.

XOMA Ltd. and Kaketsuken have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new XOMA antibody phage display library, and a suite of integrated information and data management systems.

XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced the expansion of its development strategy for its XOMA 052 antibody to interleukin-1 beta to include effects on cholesterol lowering, reducing plaque deposits and damage to heart muscle and resulting long-term effects that can lead to heart attack, stroke and ...

Vivus Inc. promoted Peter Tam, its chief operating officer, to president. That title was held previously by CEO Leland Wilson, who will now be just CEO.

XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced that the company will host a conference call and webcast on Monday, November 9 at 9:00 a.m. Eastern time to discuss third quarter 2009 financial results and provide a general business update.

Xoma Ltd. will receive $8 million from the Japanese research foundation Kaketsuken to share its antibody research and development technologies and a suite of information and data management systems.

New York, NY -- XOMA Ltd. ; Biostar Pharmaceuticals, Inc. ; Idenix Pharmaceuticals, Inc.

XOMA, Ltd , a leader in the discovery and development of antibody therapeutics, announced today the appointment of Susan Kramer, Dr.

BeaconEquity.com announces an investment report featuring biopharmaceutical company XOMA Ltd.

XOMA Ltd. today announced plans for the Phase 2 clinical development of its anti-inflammatory drug candidate to interleukin-1 beta , XOMA 052, designed for the treatment of the inflammatory cause of cardiovascular, diabetes, autoimmune and other diseases.

September 30, 2009 ATG trading at $3.86 on a volume of 735,719 shares. In a press release out on September 30, 2009 ATG Launches Catalyst Program to Drive Commerce Innovation New program provides code, insight to help customers and partners maximize their investments and embrace emerging technologies, including mobile and social commerce CAMBRIDGE, ...

The stock has shown incredible bullishness but it suffered a bit of consolidation despite some news today.

XOMA Ltd. expanded its biodefense programs to include the development of a novel antibody that has been shown by Dana-Farber Cancer Institute and Harvard Medical School researchers to neutralize group 1 influenza A viruses, including the H1N1 and the H5N1 strains.

XOMA Ltd. announced today that it has received notice from the NASDAQ Stock Market that for the 30 consecutive business days preceding September 15, 2009 the bid price of XOMA's common shares closed below the minimum $1.00 per share requirement under Marketplace Rule 4450 for continued inclusion on the NASDAQ Global Market.

Xoma Ltd. will repay the full $44.2 million remaining on a Goldman Sachs loan bogged down by its ties to the ill-fated Genentech drug Raptiva.